Yellow Risk Level


You are considered INTERMEDIATE-1 RISK. According to one study1 median Intermediate-1 survival for MF patients is estimated to be 14.2 years. Other prognostic scales2 using additional risk factors estimate much shorter survival times for higher levels of risk.

Intermediate-1 Risk implies considerable uncertainty about your condition. Without further treatment half of the patients in your risk category will live longer than 14 years. But others may turn out to be facing a more aggressive disease course.  On average fifteen percent of patients in the Intermediate-1 Risk category will die of their disease within the next two years.

Review this result with your hematologist. There may be additional features of your disease that help in predicting its course.  It is never too early to learn about your transplant options. For some patients this may be the right time to undergo a transplant or consider clinical trial. For others, it may be better to wait. In any case, meeting with your prospective stem cell transplant physician at this point is a good idea.

Because of the great differences among patients, survival figures are only approximate. A patient’s condition, genetic predisposition, and co-morbidities are just some of the factors that play a role in longevity. It is important to review your Risk Level with your hematologist both for accuracy and for inclusion of additional factors that might impact your therapeutic options.  Some of those factors are fibrosis grade, swollen spleen, transfusion dependence, high risk mutations, and defective chromosomes

What is known for certain is that qualified patients who start stem cell transplant in good condition and early enough in the MF disease process have far better outcomes than patients who wait until the onset of end-stage symptoms.3

See Notes on MPN mutations for details on your individual mutations

    1. Passamonti, Blood, 2010 115:1703-1708  
    2. Gangat et al., J Clin Oncol. 2011, February
    3. Scott, et al.,  Blood, 2012 Mar 15; 119 (110): 2657-2664)